retatrutide approval status october 2025 What is retatrutide? Retatrutide FDA Approval Status: July

While real-world data on the level of adherence to dual GLP1-RA/GIP agonists are not available to date, some considerations can be drawn from available clinical trials and experiences with other pharmacological classes

Publication bias was evaluated visually through funnel plots and formally using Eggers test

Dulaglutide can be increased from 1.5 mg to 3.0 mg or 4.5 mg in T2D not well managed by metformin to achieve HbA1c and weight reduction comparable to clinically relevant levels with the same safety [282]

The significance between the mean values for each study was evaluated using Student t tests for comparisons of two groups

Funding This study was funded by University of Birmingham, UK, from 1 August 2016

Side Effects and Safety Common side effects include gastrointestinal discomfort